跳到正文
← 返回论文列表与筛选
阅读说明

本页整理公开书目信息,不生成学术质量评分。AI 解读根据题名及所注明的摘要或原文片段生成,未完成全文核验,可能有误;具体假设、证明与结论请核对原文。摘要保留来源文本,未经模型改写。

DOI 首次登记不等于接收或发表日期。部分更正、评论等条目没有独立摘要;缺少可靠材料时保留待补状态。

本页为预印本版本;arXiv 收录、作者填写的期刊信息以及作者既有发表经历,都不单独证明本篇已接收。作者发表记录按 OpenAlex 身份与完整姓名、本站覆盖期刊 ISSN 及正式卷期核对,只展示已核实例,档案仍可能误合并。

引用量采用 OpenAlex 单条关联记录,不合计多个记录;关联记录可能包含正式发表版本,不等于此版本单独引用。缺失不视为零,引用指标不代表论文质量。

关注作者按书目中的完整姓名匹配,同名和姓名变体需人工辨别。相关论文先按共享细分方向和具体方法排列,再参考通用方法与发表日期。

分类依据与纠错

AI 根据所提供的论文材料归类:摘要估计异质处理效应,目标是两种处理下条件生存分布随时间的差异。

反馈分类问题

Targeted learning of heterogeneous treatment effect curves for right censored or left truncated time-to-event data

右删失或左截断生存数据中异质处理效应曲线的目标学习

正在核对关联版本…

代码、数据与补充材料

正在核对对应版本的资源…

关注这篇论文的作者
Matthew Pryce
Karla Diaz-Ordaz
Ruth H. Keogh
Stijn Vansteelandt

右删失或左截断生存数据中异质处理效应曲线的目标学习

研究问题
在事件时间结果存在右删失或左截断时,如何估计二元处理对个体条件生存概率的差异,并保持效应曲线的时间平滑性?
方法与思路
作者提出 surv-iTMLE 目标学习程序,同时处理右删失和左截断,并对条件生存概率差曲线施加平滑性与有界性要求。
材料陈述的贡献
摘要称,模拟中该方法改善了有限样本效应估计的偏差与平滑性,并用于非小细胞肺癌免疫治疗的异质生存效应分析。
阅读关注点
应核对处理、删失与截断的识别条件,目标更新如何利用时间结构,以及平滑约束是否影响推断和模拟比较的公平性。
阅读边界
所给版本为 arXiv 预印本,同行评审与期刊接收未核实;摘要未列出识别条件、区间推断性质或偏差改善的具体幅度。

原文摘要

In recent years, there has been growing interest in causal machine learning estimators for quantifying subject-specific effects of a binary treatment on time-to-event outcomes. Estimation approaches have been proposed which attenuate the inherent regularisation bias in machine learning predictions, with each of these estimators addressing measured confounding, right censoring, and in some cases, left truncation. However, the existing approaches are found to exhibit suboptimal finite-sample performance, with none of the existing estimators fully leveraging the temporal structure of the data, yielding non-smooth treatment effects over time. We address these limitations by introducing surv-iTMLE, a targeted learning procedure for estimating the difference in the conditional survival probabilities under two treatments. Unlike existing estimators, surv-iTMLE accommodates both left truncation and right censoring while enforcing smoothness and boundedness of the estimated treatment effect curve over time. Through extensive simulation studies under both right censoring and left truncation scenarios, we demonstrate that surv-iTMLE outperforms existing methods in terms of bias and smoothness of time-varying effect estimates in finite samples. We then illustrate surv-iTMLE's practical utility by exploring heterogeneity in the effects of immunotherapy on survival among non-small cell lung cancer (NSCLC) patients, revealing clinically meaningful temporal patterns that existing estimators may obscure.

笔记与分组